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Endometriosis is a complex, multifactorial, reproductive disorder present 
in approximately 10-15% of adult women between the ages of 25-35. This 
disorder occurs when endometrial glands and stroma grow ectopically on the 
surface of the ovaries, pelvic peritoneum, fallopian tubes, and the uterus. 
Endometriosis causes varying degrees of painful symptoms and infertility in 
infected individuals. Three main theories of endometrial accumulation attempt 
to explain the etiology of this elusive disease. There have been various 
approaches to staging of endometriosis symptoms that attempt to standardize 
classification as well as predict pain and infertility. Angiogenesis, necessary to 
the survival of endometrial tissue, along with immune dysfunction and evasion 
have been examined as possible contributing factors to the development of 
endometriosis. Certain angiogenic factors are upregulated in ectopic endometrial 
tissue and endometriotic lesions, while decreased cytotoxicity of T cells is shown 
to be an abnormal immune process observed in individuals with this disorder. 
Other factors including exposure to environmental toxicants, diet, and 
population specific polymorphisms have also been examined for their role in this 
disease. While various genetic variations have been identified as increased risk 
factors for endometriosis in certain populations, there has not been a specific 
genotype that demonstrates increased risk for this disease in all populations. 




primates, are primarily responsible for the advancement of our understanding of 
this disease. Although limitations exist for animal models, they have been an 
important contributor to current research. There is no cure for endometriosis, but 
various treatment options exist for both pain and infertility. The purpose of this 
thesis is to review current literature relevant to the etiology, development, and 
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Chapter I: Introduction 
Endometriosis is a female reproductive disorder present in approximately 
15% of adult women between the ages of 25-35 (Macer 2012). This disorder 
occurs when the endometrial tissue (cells that line the uterus) grows in other 
areas of the body. This abnormal growth of endometrial tissue, is referred to as 
ectopic endometrium and can occur anywhere in the body, but is most 
commonly observed in the pelvis—on the outer surface of the ovaries, fallopian 
tubes, or the uterus.  
The cyclic shedding of ectopic endometrium within the abdomen can 
cause irritation; lower back, intestinal, or pelvic pain, heavy menstrual periods or 
spotting between periods, dysmenorrhea, dyspareunia, and infertility (Constanti 
1998). The etiology of endometriosis is unknown, however, there are three major 
theories that attempt to explain the origin of this disease. The most commonly 
accepted theory is that of retrograde menstruation proposed by John A. 
Sampson, M.D. in 1927 described below (Alford 2010). Meyer’s theory promotes 
the idea of coelomic metaplasia and Halban’s theory focuses on endometrial 
spreading via the vasculature and lymphatics. 
Endometriosis is an estrogen dependent disease. When estrogen levels 
increase during the menstrual cycle the ectopic tissue grows and then regresses 
in the absence of estrogen similar to the activity of normal uterine endometrium 
(Constanti 1998). Current research suggests that genetic variation and
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polymorphisms contribute to the disease within certain populations. A few 
animal models have been developed to study endometriosis using mice, rats, and 
nonhuman primates. While differences between the rodents’ estrous cycle and a 
woman’s menstrual cycle prevent a direct comparison of disease findings, there 
is still much to learn about disease etiology using these models. A specific 
species of baboon has also been developed to simulate endometriosis and has a 
similar menstrual cycle to that of a human, but it is difficult to perform extensive 
experimental manipulations in this model due to the high cost associated with 
utilizing these animals. There are specific advantages and disadvantages to the 
study of each endometriosis animal model which will be discussed below. 
Current research also explores other factors potentially influencing the 
development of endometriosis. These factors include angiogenesis and immune 
response. Angiogenesis is the formation and growth of new blood vessels. This is 
required for the development and survival of endometrial tissue; without a 
blood supply there would be no oxygen or nourishment necessary for 
maintaining this tissue. Studies have explored the role of angiogenic factors in 
endometriosis development.  
Another such factor includes dysfunction of the immunological response 
to the misplaced endometrium. The dysfunction of necessary immune cells 
normally recruited to the uterine lumen during the menstrual cycle could play a 
role in the ability of ectopic endometrial tissue to implant and proliferate. 
Immune cells such as macrophages and lymphocytes required to clear the 
normal shedded endometrium could lead to pathology if unable to perform their 
normal function. Also, environmental factors, such as exposure to environmental 
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toxicants and chemical pollutants, and certain foods such as fatty acids have been 
studied for their potential role in the development of this disease.  
While there is no cure for endometriosis there are treatments that help 
reduce the symptoms (Senapati 2011). This review will discuss the current 
research and literature as it pertains to the possible origins, development, genetic 
variation, pathology, and treatment of endometriosis. 
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Chapter II: The Menstrual Cycle 
2.1 Overview 
 Endometriosis is defined as glandular and stromal tissue of the 
endometrium outside of the uterus (Burney 2012). Ectopic endometrium, similar 
to eutopic endometrium, proliferates and sheds in response to hormonal 
fluctuations. These fluctuations are due to physiological changes in the ovary 
and the regulation of these changes by the hypothalamic-pituitary axis. The 
normal changes that characterize the phases of the menstrual cycle are 
responsible for variations in the histology of the reproductive tract, including the 
endometrium, the understanding of which will provide the basis of 
endometriosis pathogenesis. The changes that occur during the menstrual cycle 
in response to hormonal regulation, changes in the histology of the reproductive 
tract, and functional and mechanistic differences between eutopic and ectopic 
endometrium will be reviewed in this chapter. 
2.2 Phases of the Menstrual Cycle 
Menarche, the initiation of menses and fertility, occurs in young women 
between the ages of 9-14 (Ross 2011). During this time there are changes that 
occur to a woman’s reproductive organs. The ovaries produce the steroid 
hormones, progesterone and estrogen, which along with neural activity regulate 
these changes. The ovarian cycle in women consists of two phases: an estrogen
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dependent follicular phase and a progesterone dependent luteal phase. Due to 
the variation in hormones that are produced during the menstrual cycle, changes 
occur within the uterus that promote an environment for embryo implantation. 
The hypothalamic-hypophyseal portal system is ultimately responsible for 
regulating the changes in plasma hormone concentration (Constanti 1998). The 
hypothalamic-hypophyseal portal system moves blood between a primary 
capillary bed in the median eminence and a second capillary bed in the anterior 
pituitary. When hypothalamic peptide hormones are released into the portal 
system they are transported by the portal veins directly to the anterior lobe. 
Through the actions of Gonadotropin-releasing hormone (GnRH), the 
hypothalamus controls secretion of the gonadotrophins, follicle stimulating 
hormone (FSH) and luteinizing hormone (LH), from the anterior pituitary gland 
(Constanti 1998). GnRH is released in a pulsatile fashion from the hypothalamus 
into the portal system and travels to the anterior pituitary, where it acts on its 
receptors to cause release of the gonadotropin hormones. During the follicular 
phase of the menstrual cycle the plasma levels of FSH and LH slowly rise; this 
causes the ovarian follicles to mature. As estrogen levels increase in circulation, it 
negatively feeds back on both the anterior pituitary gland and the hypothalamus, 
this decreases the amount of estrogen produced by the ovarian follicular somatic 
cells.  
The initial rise in estrogen characterizes the follicular phase occurring the 
first 14 days of the menstrual cycle (Ross 2011). This phase is also referred to as 
the proliferative phase, because there is proliferation of granulosa and theca cells 
of the ovarian follicle and of the endometrium. Both FSH and estrogen also 
increase the sensitivity of granulosa cells for FSH by increasing the number of 
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surface receptors for this hormone. By the late follicular phase there is a switch as 
high estrogen begins to work in a positive feedback mechanism at the level of the 
anterior pituitary and hypothalamus. This positive feedback mechanism is 
responsible for the LH surge and increased levels of progesterone that occur 
during the luteal phase. Increased estrogen levels are due to a proliferation of 
estrogen secreting follicular cells and through estrogen action on both the 
hypothalamus and anterior pituitary. High estrogen levels due to positive 
feedback and the surge of LH and FSH cause release of the secondary oocyte and 
surrounding cells from the ovary. 
The luteal phase, days 15-28 of the menstrual cycle, is dependent on high 
progesterone levels (Ross 2011). Progesterone is produced by the residual 
follicular cells, which form the corpus luteum. The progesterone prepares the 
endometrium for implantation by causing the endometrium to thicken, 
vascularization to increase, and proliferation to decrease. If the secondary oocyte 
is not fertilized in the fallopian tubes, it passes through to the uterus. In the 
absence of fertilization and implantation into the uterine wall, the corpus luteum 
regresses, resulting in a decline in estrogen and progesterone levels. Without the 
sex hormones to maintain the endometrium degradation occurs (Gray 2005). The 
shedding of the endometrium with the exception of the basal layer typically lasts 
about four days and its onset starts the next cycle. 
2.3 Role of Estrogen in the Menstrual Cycle 
The steroid hormones, estrogen and progesterone, are produced in the 
ovaries by a process called steroiodogenesis (Ross 2011). These hormones, 
formed from a cholesterol precursor, are synthesized in a cyclic manner and are 
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responsible for the changes that occur in the female reproductive system. 
Estrogens are critical regulators of normal reproductive function (Heldring 2007). 
Three forms of estrogen exist as shown in Figure 2.1: 17β-estradiol (E2), estriol 
(E3), and estrone (E1). E2 is the predominant and most potent form of estrogen in 
adult pre-menopausal women. E3 increases during pregnancy and E1 is the 
major form of estrogen in post-menopausal women. 
Estrogen is important in the development of both internal and external sex 
organs and is also responsible for the female sex characteristics that develop in 
young women at puberty. Two types of estrogen receptors exist in the body and 
establish the physiological functions of estrogen, estrogen receptor alpha (ERα) 
and estrogen receptor beta (ERβ) (Burns 2012). Both receptors are part of the 
nuclear receptor family of transcription factors and are vital to the function of the 
reproductive tract, breast, bone, and brain (Heldring 2007). Accepted research 
shows marked functional differences between these two receptors, including the 
opposite effects these receptors induce on promoters of genes involved in 
proliferation. Estrogen bound to ERα has been shown to induce the transcription 
of pro-proliferative target genes, such as cyclin A and c-Myc mRNA (Zhang 
2009), whereas ERβ is responsible for activating anti-proliferative target genes 
and producing anti-inflammatory effects (Heldring 2007). 
As previously mentioned, LH is released from the anterior pituitary and 
stimulates theca cells to produce testosterone. Under the actions of LH, the lipid-
soluble molecule cholesterol is converted to pregnenolone by the cytochrome 
P450 cholesterol side-chain cleavage enzyme complex in theca cells (Constanti 
1998). Through a series of reactions pregnenolone is converted into testosterone, 
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which traverses the theca cell and basement membrane and diffuses into 
granulosa cells. FSH binding to its receptor on granulosa cells increases 
aromatase enzyme synthesis and activity, which is responsible for converting 
testosterone into estradiol. 
Progesterone, secreted by the corpus luteum during the luteal phase of 
menses, enables the uterus to adapt for pregnancy by allowing for changes in the 
endometrium (Ross 2011). The rise and fall of estrogen and progesterone 
characterize the menstrual cycle. During the menstrual phase of the uterine cycle, 
regression of the corpus luteum occurs, and decreases in estradiol and 
progesterone allow for the endometrial lining to shed. This cyclic sloughing and 
regenerating feature distinguishes endometrial tissue and thus endometriosis 
from other pathology such as cancerous growths.  
2.4 Histology of the Female Reproductive System and Endometrium 
The female reproductive tract is composed of a pair of almond-shaped 
ovaries and fallopian tubes that come together at the uterus (Ross 2011). The 
primary functions of the ovaries are oogenesis and steroidogenesis. A center 
medullary region and an outer cortex form the bulk of the ovarian structure, 
while the surface is covered in a layer of simple cuboidal cells, referred to as the 
germinal epithelium. The medulla contains loose connective tissue, blood 
vessels, and lymphatics; while the cortex surrounding the medulla contains the 
follicles surrounded by smooth muscle fibers. The female germ cells, oogonia, 
undergo mitosis and stop in prophase I of meiosis before they become 
primordial follicles (Blake 2012). This occurs in the fetus. The long period of 
meiotic arrest leaves the primary oocyte vulnerable to potentially harmful 
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environmental influences that could develop years after birth. Simple squamous 
follicular cells surround the primary oocyte forming the primordial follicle. 
At the start of the menstrual cycle, due to increasing levels of FSH, a 
group of primordial follicles enlarge and become primary follicles (Constanti 
1998). The primary and antral stages of development are referred to as the 
growing follicle (Blake 2012). The process of developing an ovulatory follicle 
from this early stage takes 3-4 menstrual cycles. The transition between 
primordial follicle and primary follicle involves morphological changes; the 
oocyte begins to enlarge and the surrounding squamous cells become cuboidal 
(Ross 2011). The change from squamous to cuboidal of the surrounding follicular 
cells characterizes a primary follicle. The growing oocyte emits a gel-like, 
nutritive protein material called the zona pellucida, which separates it from the 
follicular somatic cells. The single layer of follicular cells undergoes rapid 
proliferation and forms the granulosa cell layer. The stromal cells surrounding 
the follicle form a sheath of connective tissue called the theca folliculi made up of 
a theca interna and theca externa. The theca interna is highly vascularized and 
contains LH receptors, while the theca externa contains smooth muscle. 
As the primary follicle continues to grow into the antral follicle the 
granulosa cell proliferates and becomes 6-12 cell layers thick (Ross 2011). The 
granulosa cells that are associated with the oocyte are referred to as the cumulus 
oophorus and the antrum is formed from the combined fluid-filled cavities 
between granulosa cells. Through a process not completely understood one 
follicle continues to grow and becomes the dominant or Graafian follicle 
extending throughout the entire cortex of the ovary and causing a bulge. The 
other follicles at different stages regress and are reabsorbed through atresia.  
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The LH surge causes ovulation in which the secondary oocyte and 
surrounding cells are released from the Graafian follicle (Ross 2011). The cells of 
the cumulus oophorus immediately surrounding the oocyte and remain with it at 
ovulation are called the corona radiata. The secondary oocyte and the corona 
radiata exit the ovary through a break in the germinal epithelial layer and move 
into the fallopian tubes. The secondary oocyte is a product of the first meiotic 
division. The daughter cells of the primary oocyte each receive the same amount 
of chromatin, however, one daughter cell receives a majority of the cytoplasm 
and becomes the secondary oocyte. The second daughter cell with a lesser 
amount of cytoplasm becomes the first polar body. After ovulation the secondary 
oocyte is only viable for about 24 hours, if fertilization fails to occur, the 
secondary oocyte degenerates. 
The wall of the fallopian tubes, also called uterine tubes or oviducts, are 
made up of three layers (Ross 2011). The outer most layer is the serosa or 
peritoneum, the middle layer the muscularis, and the innermost layer the 
mucosa. The mucosal lining of the uterine tubes contains both ciliated and non-
ciliated simple columnar epithelium. The cilia, composed of an internal core of 
microtubules, are apical modifications that exist on the surface of epithelial cells. 
These microscopic structures beat together in order to aid in moving the 
secondary oocyte or embryo (if fertilized) from the oviducts into the uterus. The 
randomly dispersed non-ciliated peg cells provide nourishment for the embryo. 
The uterus is a muscular organ about 7 cm long, 4 cm wide, and 2.5 cm 
thick (Ross 2011). It is divided into three regions: the body, the fundus, and the 
cervix. The uterine wall of the body and the fundus is composed of the 
endometrium and myometrium. The myometrium is the smooth muscle layer of 
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the uterus that has the ability to contract in response to stimulation (Blake 2012). 
Oxytocin stimulates uterine contraction at the end of pregnancy by acting on its 
receptor and through initiation of prostaglandin synthesis. Oxytocin has an 
increased effect due to estrogen, which sensitizes the myometrium to oxytocin by 
up-regulating its receptor. Progesterone has the opposite affect and causes 
suppression of uterine contractions. 
The mucosal lining of the uterus is called the endometrium, which can be 
divided into the stratum basale and the stratum functionalis (Ross 2011). The 
stratum basale, or the basilar zone, gives rise to the stratum functionalis that 
grows and is then shed each month. The monthly changes that occur in the 
endometrium correspond to the hormonal changes of the follicular and luteal 
phases of the ovarian cycle (Gray 2005).  
The endometrial tissue that lines the uterine cavity is made up of simple 
columnar epithelium (Young 2000). The supporting stroma contains simple 
tubular glands. The endometrium is 1-2 mm thick at the beginning of a cycle and 
the glands are straight, non-secreting, and lined with columnar epithelium (Gray 
2005). Early in the proliferative phase, re-epithelialization or resurfacing occurs, 
in which the remnant basilar zone of the uterine glands proliferate and migrate 
to cover the endometrial surface stripped from its mucosa by menstrual 
shedding. This process concludes about 5-6 days after the start of shedding.  
As ovarian produced estrogen levels rise throughout the proliferative 
phase the endometrial cells begin to rapidly divide (Young 2000). Estradiol acts 
through receptors located on stromal and epithelial cells, which also causes the 
simple tubular glands to proliferate, forming numerous glands. The proliferative 
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phase is maintained until ovulation by the increasing synthesis and secretion of 
estrogen from the developing ovarian follicles. 
The secretory phase of the uterine cycle occurs after ovulation and is 
characterized by progesterone and estrogen induced endometrial changes (Gray 
2005). Estrogen causes progesterone receptor expression and is therefore an 
important regulator of progestational effects (Blake 2012). Progesterone’s effects 
on endometrial stromal cells, also referred to as the decidual reaction, are evident 
in the early secretory phase. During this phase the endometrium grows up to 6 
mm and the glands become highly coiled (Young 2000). Endometrial stromal 
glands are induced by progesterone to produce a thick, glycogen-rich secretion, 
which is an important nutritive factor for the embryo while vascular connections 
are being established with the mother’s vasculature. In the absence of 
fertilization, the late secretory phase of the menstrual cycle shows a regression of 
glandular secretory activity. 
In the absence of fertilization the menstrual phase of the uterine cycle 
begins (Young 2000). As previously mentioned, without progesterone, the 
endometrium can no longer be maintained and is shed during menstruation. 
Blood and necrotic endometrium appear in the uterine lumen, to be discharged 
from the uterus and out through the vagina as menstruation (Gray 2005). During 
this time FSH secretion is induced, causing a new cycle of follicle development 
and production of estrogen, which begins the process of resurfacing. Although 
the process of menstruation represents the end-point of the cycle of endometrial 
changes, the first day of menstruation also marks the beginning of a new 
proliferative phase. 
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The uterine blood supply spans from the myometrium through both 
layers of the endometrium and is predominantly arterial (Ross 2011). The 
distinguishing arrangement of the endometrium’s arterial supply has essential 
influences on the menstrual cycle (Young 2000). Branches of the uterine artery 
extend through the myometrium and bifurcate into two different types of 
arteries, spiral arteries and straight arteries, as they extend into the endometrial 
layer.  
The straight arteries are short and supply the stratum basalis of the 
endometrium (Young 2000). Spiral arteries are opposite; they are long, coiled and 
thick-walled. These arteries supply the surface of the endometrium giving off 
numerous branches that surround the stromal glands. The spiral arteries, unlike 
straight arteries, react to hormonal changes of the uterine cycle. The end of the 
secretory phase, characterized by inhibition of estrogen and progesterone 
secretion, causes the spiral arteries to constrict and leads to an ischemic phase. 
This phase immediately precedes menstruation and induces degeneration of the 
endometrium. The spiral artery along with lacunae and capillary beds are part of 
the stratum functionalis, which is shed and then reformed each month (Ross 
2011). 
2.5 Ectopic Endometrium 
 Eutopic endometrium is thought to be the tissue from which 
endometriosis develops. Because of this, a comparison between ectopic and 
eutopic endometrial tissue is important to the study of this disease. Ectopic 
endometrium, no matter the location, typically resembles the eutopic 
endometrial characteristics of proliferation and shedding. For this reason the 
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hormonal responses of both tissue types is presumed to be similar. However, 
studies have shown this is not the case and that other factors are involved with 
the development and regulation of ectopic endometrial lesions (Metzger 1993). 
 Jones et al (2009) examined the ultrastructure of ectopic peritoneal lesions 
using electron microscopy and immunohistochemistry. Heterogeneity was 
observed among the structure of endometriotic lesions suggesting non-
uniformity, dissimilar to eutopic endometrium. A mix of all three cell types 
(squamous, cuboidal, and columnar) were observed in the excised peritoneal 
lesions. The most similar structural observation was seen in a biopsy taken on 
day 9 of this study, showing columnar glandular tissue, euchromatic nuclei, and 
a normal distribution of organelles. Certain homogenous features were noted in 
this study including a significant lack of glycogen accumulation normally seen in 
the second part of the menstrual cycle.  
As previously mentioned, glycogen is the main product of endometrial 
glands, and is important in nourishing an embryo after implantation into the 
uterine wall. The lack of glycogen observed in these ectopic lesions may be 







Figure 2.1 Estrogen Metabolites (From Hammond CR, Soules M: Clinical 
significance of estrogen metabolism and physiology. Contemp OB/GYN 11:41, 
1978). Copyright © 2004 - 2011 Lippincott Williams & Wilkins, Two Commerce 
Square, 2001 Market Street, Philadelphia, PA 19103 U.S.A. All rights reserved.
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Chapter III: Theories of Endometrial Accumulation 
 
3.1 Overview of Endometriosis Theories 
 Three main theories of endometriosis etiology exist today. All three have 
received varying amounts of support (Vinatier 2001), however, the most 
accepted theory of endometriosis pathogenesis is Sampson’s theory of retrograde 
menstruation. Because retrograde menstruation occurs in a larger percentage of 
menstruating women than those diagnosed with endometriosis, other factors 
must be involved in the pathogenesis. This theory is the basis for a lot of current 
research that seeks to find potential immunologic, angiogenic, and 
environmental factors that may allow for the implantation and development of 
misplaced endometrial tissue.   
The other widely known theories of endometriosis etiology include, 
Meyer’s theory of coelomic metaplasia and Halban’s theory of lymphatics and 
vascular metastasis, which were developed around the same time (Hoffman 
2011). The theory of coelomic metaplasia is based on the potential morphological 
changes of cells found in the ovary; because cells that make up both the ovary 
and the uterus are derived from the same precursor cell, the potential for 
metaplasia exists. Halban’s theory of lymphatics and vascular metastasis 
suggests that endometrial tissue is taken up through the lymphatic spaces and 
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the vasculature, causing distant lesion formation. These theories along with 
related literature will be reviewed here. 
3.2 Sampson’s Theory of Retrograde Menstruation 
 In 1927 John A. Sampson, M.D. published a paper entitled “Metastatic or 
Embolic Endometriosis, due to the Menstrual Dissemination of Endometrial 
Tissue into the Venous Circulation” (Sampson 1927). This paper discussed this 
theory of endometriosis etiology based on retrograde menstruation and 
implantation. Sampson’s theory was formed from his own observations during a 
series of hysterectomies performed during various stages of the menstrual cycle. 
Sampson’s primary theory suggests that the pathology of endometriosis 
occurs when endometrial tissue is shed from the mucosa of the uterus and flows 
back into the oviducts and into the peritoneum (Sampson 1927). Endometriosis 
can be induced in the baboon by endocervical canal resection, which prevents 
endometrial tissue from being discharged from the uterus and out through the 
vagina; this simulates retrograde menstruation (Dehoux 2011). This induced non-
human primate model for endometriosis, discussed in greater detail in Chapter 
9, supports this theory. 
Sampson also suggested that endometrial tissue maybe taken into venous 
circulation of the uterus during menstruation, which would account for the 
etiology of endometrial tissue growing away from the uterus, such as on the 
vagina, groin, and rectum (Sampson 1927). 
While retrograde menstruation has been shown to occur in up to 90% of 
women (Bokor 2009 and Burney 2012) with viable endometrial cells found in the 
fallopian tubes and in the peritoneum (Halme 1984), it would be expected to 
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display a higher incidence of endometriosis. This indicates that other factors 
besides endometrial tissue found outside of the uterine mucosa are necessary for 
the formation of this disease (Alford 2010). 
3.3 Meyer’s Theory of Coelomic Metaplasia 
Meyer’s theory, also commonly referred to as the theory of coelomic 
metaplasia, explains only ovarian and pelvic peritoneal endometriosis (Meyer 
1919). This theory is established on the basis that both the germinal epithelium of 
the ovary, the pelvic peritoneum, and that of the uterus are derived from the 
same precursor cell. It infers that the germinal epithelium of the ovary and the 
pelvis can morph by metaplasia into endometrial tissue (Vinatier 2001). This 
theory is appealing due to its suggestion of the etiology of endometriosis without 
menstruation playing a factor. However, there are also several facts unexplained 
by this theory.  
First, if peritoneal metaplasia explains the origin of this disease, a similar 
disease should be observed in males (Vinatier 2001). Coelomic mesothelium, also 
mesodermal epithelium, is one of three common cell sources of testes and 
ovarian development (Ross 2011). In males, coelomic mesothelium gives rise to 
Sertoli cells and the primary sex cords. As development continues, the primary 
sex cords differentiate into the seminiferous cords, which later develop into the 
seminiferous tubules, straight tubules, and rete testis. If metaplasia occurs with 
these precursor cells in women, it would be most likely, also be seen in men.  
Secondly, coelomic metaplasia would be observed in all tissues derived 
from the coelomic epithelium, which include both striated and smooth muscle, 
the heart, blood and lymphatic vessels, the spleen, kidneys, and the adrenal 
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cortex (Ross 2011). Finally, if coleomic metaplasia mimics typical metaplasia, 
then endometriosis should be more common in older women. 
While this theory makes sense, because cells of the ovary, pelvic 
peritoneum, and endometrial cells are both derived from the same coelomic 
precursor cell in the developing embryo, it has been difficult to provide scientific 
evidence to support it (Alford 2010). However, studies that examine benign and 
malignant epithelial ovarian tumors and the correlation between endometriosis 
may provide support for this theory. Epithelial ovarian tumors are considered to 
be derivatives of germinal epithelium; the presence of ovarian surface epithelium 
could be accounted for by coelomic metaplasia (Somigliana 2006). 
3.4 Halban’s Theory of Lymphatic and Vascular Metastasis 
 Another theory of endometriosis etiology is that of vascular and 
lymphatic metastasis (Vinatier 2001). Halban suggested that during the invasion 
of the myometrium by its mucosa, bits of the endometrial tissue are taken up into 
lymphatic spaces between muscle bundles of the uterine wall and are 
transported to superficial lymphatics. This theory suggests that distant lesions 
are formed by endometrial tissue being taken up by the blood supply and 
lymphatic vessels in the uterus and transported to other areas of the body. While 
this theory could potentially explain distant lesions, it does not explain the 
particular location of most endometrial lesions, which is on the surface of ovaries 
or within the abdominal peritoneum. 
3.5 Conclusions 
 These theories of endometriosis etiology have provided researchers with a 
starting point, leading to some important discoveries about factors involved in 
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the development of this disease. However, these theories have been difficult to 
support and therefore remain inconclusive. 
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Chapter IV: Diagnosing Endometriosis 
4.1 Overview 
The primary method of diagnosing endometriosis today is via 
laparoscopy, which sometimes includes taking a biopsy for a histological 
diagnosis (Hoffman 2011). Due to the varying degrees of endometriosis among 
women there have been attempts to create a standardized classification system in 
order to objectively evaluate the extent of the disease based on the amount of 
ectopic endometrial tissue and the appearance of the endometriotic lesions.  
The first classification system, provided by the American Fertility Society 
(AFS) in 1979, was a scoring system that experimented with labeling the severity 
of the disease based solely on observation (Adamson 2011). Since then there have 
been two revisions of this classification systems as well as other methods of 
classification. These include the ENZIAN classification system and the 
Endometriosis Fertility Index (EFI), which will be discussed in this chapter. 
4.2 The American Fertility Society Classification System 
The AFS, later renamed the American Society for Reproductive Medicine 
(ASRM), revised its classification system in 1985 and is currently the best known 
and most widely used classification system for endometriosis (Haas 2013). The 
revision distinguishes between superficial and invasive levels of the disease. 
According to the revised classification system, there are four stages 
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of endometriosis: stage I (minimal), stage II (mild), stage III (moderate), and 
stage IV (severe). Staging is determined by five factors, including the location of 
the endometrial lesions, the size of the lesions, the presence of adhesions, the 
extent of the adhesions, and the degree of obliteration of the posterior cul-de-sac 
(Adamson 2010). Similar results were published in support of the AFS’s revised 
classification of endometriosis and concluded that visual documentation of 
endometriotic lesions were reproducible and therefore sufficient in making a 
determination on the stage of endometriosis according to the American Fertility 
Society classification (Rock 1995). 
The ASRM produced a second revision of the classification system for 
endometriosis in 1997 in order to update the system based on surgical findings 
(rASRM classification system). There were no apparent changes made to the 
stages defined in the 1985 classification, however, an additional description of 
lesion morphology (white, red, and black) was included in this revision. While 
the second rASRM’s scoring system is the most commonly used system to 
determine the level of severity of endometriosis, studies have shown that this 
classification does not predict fertility or the severity of associated pain in 
individuals (Guzick 1997). This classification system also lacks assessment of 
deep infiltrating endometriosis. A work sheet for this classification system is 
shown in figure 4.1 However, both the ENZIAN system and the EFI have set out 
to accomplish this by making other scoring systems that measure pregnancy 
rates for endometriosis patients as well as developing methods in predicting 
pain. These scoring systems are discussed in the following sections. 
 In order to determine the rASRM score, numbers are given to 
endometriotic lesions found in the peritoneum and ovaries using points that are 
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to represent these lesions (Haas 2013). In addition, points are given for adhesions 
on the ovaries and the oviducts as well as for partial or complete posterior cul-
de-sac obliteration. Each stage is scored as follows: stage I (1-5 points), stage II (6-
15 points), stage III (16-40 points), and stage IV (>40 points). 
4.3 The ENZIAN Classification System 
 Deep infiltrating endometriosis (DIE) is a special type of endometriosis 
that infiltrates the peritoneal surface >5 mm (Koninckx 1994). These lesions are 
extremely active and significantly correlated with pelvic pain (Koninckx 1991). 
The ENZIAN classification system was developed because the rASRM 
classification of endometriosis does not assess this particular development of 
endometriosis. 
The ENZIAN classification system was established in 2005 with the 
intentions of supplementing the rASRM’s classification of endometriosis rather 
than challenging it. The ENZIAN classification system attempts to provide a way 
to classify DIE. In February 2011 the second revision of the ENZIAN 
classification system was released. The revised classification system divides the 
retroperitoneal structures into three separate compartments as follows: 
Compartment A (retrovaginal septum and vagina), Compartment B (sacrouterine 
ligament to pelvic wall), and Compartment C (rectum and sigmoid colon) (Haas 
2012). Similar to the rASRM system, the severity rating for each compartment is 
indicated by a grading scale. The grading system is 1-3 based on the depth of 
invasion: a grade of 1 will be used to indicate invasion <1 cm, grade 2 indicates 
invasion 1-3 cm, and grade 3 indicates invasion >3 cm. While the ENZIAN 
system of classification is meant to supplement the rASRM classification of 
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endometriosis, it is not yet internationally accepted. A worksheet for the 
ENZIAN classification system is shown in figure 4.2. 
4.4 The Endometriosis Fertility Index 
As previously mentioned, classification of endometriosis based on the 
rASRM classification system is unable to predict fertility in women suffering 
from endometriosis. The EFI staging system was created in order to effectively 
assess fertility outcomes based on clinical data (Adamson 2010). This clinical tool 
has been deemed clinically useful for patients surgically diagnosed with 
endometriosis attempting non-IVF conception. A study was performed using 
data collection and statistical analysis on 579 infertile patients in order to 
produce this method of staging. After creation of this fertility index, data was 
then collected and EFI scores were calculated on an additional 222 patients. 
Subsequently, the actual pregnancy rates compared with the EFI predicted rates. 
The EFI score is a sum total of two separate scores: a historical factors 
score and a least function (LF) score. The historical components evaluated in 
preliminary analyses were age, duration of infertility, and pregnancy history 
(Adamson 1993). These determinants were also used to make up the historical 
factors score, while the LF score based on surgical observations was used to 
supplement this (Adamson 2010). The LF score is determined by the observation 
of dysfunction of the reproductive structures involved in reproductive processes 
including, the fallopian tubes, fimbria, and ovaries. The points used to calculate 
LF scores are 0= absent or nonfunctional, 1= severe, 2= moderate, 3= mild 
dysfunction, or 4= normal; these points are given by a surgeon with respect to 
the capability of the organ/structure to function. Scores for each structure 
 25	  
(fallopian tubes, fimbria, and ovaries) were given separately for each side and 
then combined. After all scores were given, they are summed for both the right 
and left side of each structure. The lowest, corresponding to the severity for the 
right and left of each side, are combined for the LF score. The final EFI score is 
then calculated by adding the historical factors score and the LF score together. 





Figure 4.1 "Revised American Fertility Society Classification of Endometriosis: 
1985." Revised American Fertility Society Classification of Endometriosis: 1985. 





Figure 4.2 The revised ENZIAN classification of endometriosis. Reprinted from 
Acta Obstetricia et Gynecologica Scandinavica, Dietmar Haas, Omar Shebl, 
Andreas Shamiyeh, Peter Oppelt, “The rASRM and the Enzian classification for 
endometriosis: their strengths and weaknesses,” 3-7, © 2012 The Authors © 2012 
Nordic Federation of Societies of Obstetrics and Gynecology, with permission 




Figure 4.3 The EFI Surgery Form. Reprinted from Fertility and Sterility, Volume 
94, G. David Adamson and David J. Pasta, “Endometriosis fertility index: the 
new, validated endometriosis staging system,” 1609-1615, © 2010, with 
permission from Elsevier. 
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Chapter V: Angiogenesis 
5.1 Overview 
Angiogenesis, the formation of new blood vessels from preexisting 
vessels, is crucial to the development, implantation, and progression of 
endometriosis. In normal women, endometrial stromal cells release angiogenic 
factors, which signal the vasculature of the stratum functionalis to proliferate. 
Vascular endothelial growth factor (VEGF) is the most studied pro-angiogenic 
factor that signals angiogenesis and vascularization (Hoffman 2011). Endothelial 
cells are steadily experiencing shear stress or the pressure applied by blood flow. 
Shear stress, inflammation, and hypoxia, or oxygen deficiency, in cells induces 
VEGF production (Ross 2011). The role of VEGF and other angiogenic factors are 
among current research topics in endometriosis pathology. 
 Ectopic endometrial tissue requires angiogenesis for development, which 
suggests its potential role in endometriosis pathology. The complex process of 
angiogenesis begins with degradation of the basement membrane of a capillary 
or vein, migration and proliferation of endothelial cells, sprouting and adjoining 
of two vessels, and finally maturation of those vessels. In addition to VEGF, 
Fibroblast Growth Factors (FGFs), Platelet-derived Growth Factor (PDGF), 
Transforming Growth Factor-alpha (TGFα), Transforming Growth Factor-beta 
(TGFβ), and Tumor Necrosis Factor-alpha (TNFα) are the most significant 
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inducers of angiogenesis as it relates to the female reproductive system. The role 
of VEGF, FGF, and PDGF in the normal female reproductive tract and in 
endometriosis will be presented below. 
5.2 VEGF, FGF, and PDGF in the normal female reproductive tract 
VEGF is a secreted heparin-binding, dimeric glycoprotein that acts as a 
chemo-attractant to endothelial cells. It is crucial to blood vessel formation, as 
studies have shown that inactivation of VEGF in embryonic stem cells leads to 
malformation of blood vessels within the embryo (Ferrara 1996). VEGF has 
several isoforms encoded by a single gene (Enholm 1997). These isoforms, VEGF-
A, VEGF-B, and VEGF-C, are created through alternative splicing methods and 
have different effects on various populations of endothelial cells (Abulafia 1999). 
Tumors produce elevated levels of VEGF in order to establish a vascular supply 
(Shweiki 1993); it is believed that ectopic endometrial tissue utilizes a similar 
action for survival.  
VEGF-A is the most important angiogenic factor of the various isoforms 
and is typically studied for its role in tumor growth (Ferrara 2009). It is 
responsible for inducing both normal and pathologic angiogenesis and it is 
believed to play a central role in the growth and maintenance of endometriosis 
(Ferrara 2009 and Donnez 1998).  VEGF-C was determined to be the ligand for 
the VEGF receptor expressed predominantly on venous endothelium of early 
embryos and lymphatic endothelium of adult tissues (Enholm 1997). This 
isoform of VEGF is increased in endometrium and promotes endothelial 
functions and vascular permeability (Xu 2013). VEGF-B, like VEGF-A and VEGF-
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C, is expressed in most tissues, but its greatest concentrations are in the heart and 
skeletal muscle (Enholm 1997), which explains its lower effects on endometrium. 
During the normal menstrual cycle the angiogenic response is structured 
and controlled with rapid growth of vessels during the secretory phase and 
arrested growth shortly after (Abulafia 1999). Changes in endometrial VEGF 
mRNA expression are observed during the menstrual cycle. Its expression 
increased three to five times from the early proliferative phase to the late 
secretory phase where it was maximal (Shifren 1996). VEGF mRNA was present 
in uterine glandular epithelial cells and stromal cells. The increase in VEGF 
mRNA expression by the late secretory phase suggests that vascular endothelial 
growth factor may impact expansion and coiling of the spiral arteries. VEGF 
mRNA expression is observed in many different cell types of the female 
reproductive system that are either involved in the process of steroidogenesis, for 
example, granulosa, theca, and luteal cells; or are steroid responsive, including 
oviductal epithelium and endometrial stromal cells. VEGF expression is 
hormonally regulated and up-regulated in cells that produce steroid hormones 
(Shweiki 1993). Overexpression of VEGF leads to pathology, including cancers 
and endometriosis, which similarly require a blood supply for cell survival. 
Fibroblast growth factors (FGFs) are secreted proteins produced by 
vascular endothelial and smooth muscle cells. FGFs and their receptors are 
regulators of angiogenesis, steroidogenesis, proliferation, differentiation, 
migration, and cell-survival (Brooks 2012). FGFs are heparin-binding growth 
factors, while their receptors are part of the tyrosine kinase receptor family 
(Chaves 2012). After various studies identified expression of FGFs in 
reproductive tissue, further experimentation demonstrated the involvement of 
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FGFs in the physiological regulation of reproductive processes and ovarian 
function.  
FGF-2 is the most studied and characterized growth factor of the FGF 
family and is involved in the survival of reproductive cells. Similar to VEGF, 
FGF-2 is an angiogenic growth factor present in both normal and abnormal 
endometrium. This factor is important not only for angiogenesis in general, but 
also specifically for angiogenesis of endometrial tissue (Möller 2001). A study by 
Zhou et al (2005) demonstrated that FGF-2 could maintain oocyte survival in 
culture, but did not seem to have an effect on growth. A second study also 
demonstrated that FGF-2 prevents granulosa cell apoptosis in an in vitro study 
with rat granulosa cells (Tilly 1992). Dysregulation of the FGF/FGFR pathway 
and overexpression of FGFR have been correlated with developmental disorders, 
cancers, and endometriosis. 
 Another factor involved in angiogenesis and therefore studied in 
correlation with endometriosis pathology is Platelet-derived growth factor. 
PDGF is a protein released by platelets that induces proliferation of fibroblasts 
(Campbell 2005). The binding of PDGF with its receptor, part of the tyrosine 
kinase receptor family, initiates a signal transduction pathway enabling the 
connective tissue fibroblasts to divide. It is possible that a combination of all 
three of these angiogenic factors is necessary for the development and 
maintenance of endometriosis. 
5.3 Vascular Endothelial Growth Factor in Endometriosis 
 In order for endometriosis to progress, endometrial tissue must implant in 
an extra-uterine location and obtain a blood supply in order to grow. Active 
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endometrial lesions potentially activate angiogenesis within and around adjacent 
tissue (Abulafia 1999). Increased levels of angiogenic factors, including VEGF in 
the peritoneal fluid of women with endometriosis compared to women without 
endometriosis have been observed (McLauren 1996). This finding is consistent 
with the endometriosis requirement for angiogenesis and suggests pathology 
due to the overexpression of angiogenic factors. It was also observed that VEGF 
concentrations were significantly higher during the proliferative phase than the 
secretory phase. Taylor et al (1997) showed that increased levels of VEGF and IL-
8 in peritoneal fluid have positive correlation with the number of active 
endometriosis lesions. The same study also demonstrated a fast-acting and direct 
effect of E2 on VEGF mRNA and protein synthesis in endometrial stromal cells. 
The addition of 10 nM E2 to endometrial stromal cells caused a 50% increase in 
VEGF secretion. 
 As previously mentioned various isoforms of VEGF are responsible for 
different functions and properties of angiogenesis. A study by Xu et al (2013) 
found increased levels of VEGF-A, VEGF-B, and VEGF-C proteins in the eutopic 
and ectopic endometrium of an endometriosis nude mouse model. However, 
VEGF-A mRNA in ectopic endometrium and VEGF-C in both eutopic and 
ectopic endometrium were found to be significantly higher in patients with 
endometriosis than controls. It was also determined that VEGF-C significantly 
enhanced development and angiogenesis of endometriosis. 
 A study by Laschke et al (2007) determined that COX-2 inhibitors inhibit 
VEGF-mediated angiogenesis. COX-2 is an enzyme responsible for producing 
prostaglandins involved in inflammation, pain, and fever (Lehninger 2008). Two 
studies demonstrated that COX-2 inhibition prevents implantation of 
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endometrium at ectopic sites, which is a vital step in the survival of endometrial 
tissue outside of the uterus, and ultimately development of endometriosis. COX-
2 inhibitors and their effects will be discussed in more detail in Chapter 10. 
5.4 Fibroblast Growth Factor in Endometriosis 
 FGF-2, as previously mentioned, is an angiogenic growth factor present in 
both normal and abnormal endometrium (Bourlev 2006). This factor is important 
not only for angiogenesis in general, but also specifically for endometrial 
angiogenesis.  
FGF-2 induces angiogenesis by binding to one of its receptors FGFR-1 or 
FGFR-2 (Möller 2001). Data shows that both receptors of FGF-2 are present in 
human endometrium	  (Ferriani 1993). Specifically, both receptors were expressed 
in arteries, but not in veins during the late secretory phase. However, the 
expression of FGFR-2 in endometrial glands was observed to be unrelated to 
menstrual cycle phase (Möller 2001). 
FGF-2 has also been detected in both serum and the peritoneal fluid of 
patients with endometriosis	  (Bourlev 2006). Individuals with surgically 
confirmed endometriosis compared with controls had observed higher 
concentrations of FGF-2 during both the proliferative and secretory phases of the 
menstrual cycle. Also, the FGF-2 levels observed in the peritoneal fluid were 
significantly higher than in serum.  
5.5 Platelet Derived Growth Factor in Endometriosis 
PDGF induces its greatest effects on endometrial luminal and glandular 
epithelial cells during the proliferative phase and lesser effects in the secretory 
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phase (Chegini 1992). PDGF induces cell division of endometrial stromal cells 
suggesting a modulatory role on endometrial cell growth and differentiation. 
Surrey et al (1991) used proliferative phase stromal cells isolated from the 
endometriotic lesions biopsied from individuals with endometriosis. These cells 
grown in culture were used to model the stromal composition of ectopic 
endometrium. PDGF and physiological E2 concentrations caused a significant 
increase in proliferation of the endometrial stromal cells. This suggests that 
PDGF may play an important role in the development or maintenance of 
endometriosis. 
5.6 Conclusions: A Cooperative Role for VEGF, FGF, and PDGF 
 Data support cooperation between VEGF, FGF, and PDGF in the ability of 
ectopic endometrium to establish and maintain a new blood vessel formation. A 
study by Laschke et al (2006) determined that the combined inhibition of VEGF, 
fibroblast growth factor, and platelet-derived growth factor effectively 
suppressed angiogenesis and vessel maturation of endometrial grafts. The 
combined inhibition was more effective than inhibition of VEGF alone. 
Combined inhibition significantly reduced the size of the microvascular network 
and decreased micro-vessel density. This suggests a cross talk between VEGF, 
FGF, and PDGF in the establishment of microvascularization of endometriotic 
lesions. Thus, the ability of new endometriotic lesions to develop may strongly 
depend on the microenvironment concentrations of these angiogenic factors, and 
their inhibition may be one approach to controlling new lesion growth. 
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Chapter VI: Immunology of Endometriosis 
6.1 Immunology Overview 
 The immunology of endometriosis has been explored as a potential factor 
in the pathology of this disease. Immune cells have been shown to play a critical 
role in allowing refluxed endometrial cells to implant and grow rather than be 
eliminated. The presence of lymphocytes, natural killer (NK) cells, macrophages, 
and mast cells in endometriotic lesions suggests the influence of these immune 
cells on this disease. T lymphocytes and macrophages are the two major 
leukocyte populations found in endometrial tissue (Osuga 2011). A brief review 
of these immune system cells will give a better understanding of their role and 
importance as it pertains to endometriosis. This chapter discusses the potential 
role of immune cell populations in the pathology of endometriosis. 
6.2 Cells of the Immune System 
 The predominant cells of the immune system are lymphocytes, antigen-
presenting cells, and effector cells (Abbas 2012). There are two major types of 
lymphocytes that are distinguished based on their functions and how they 
recognize foreign substances. B-lymphocytes, the major components of humoral 
immunity, account for 20-30% of the circulating lymphocyte population (Ross 
2011). These cells are produced in the bone marrow to recognize specific 
antigens, differentiate into plasma cells, and synthesize antibodies.  
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T lymphocytes, which make up a majority of the circulating lymphocyte 
population, characterize cell-mediated immunity (Abbas 2012). These cells 
recognize intracellular microbes and either directly induce apoptosis of infected 
cells, secrete cytokines, or regulate the immune response. Three different 
subpopulations of T lymphocytes serve different functions: T helper cells, 
cytotoxic T cells (CTLs), and regulatory T cells (T regs). T cells are educated in 
the thymus to recognize and destroy foreign antigens (Ross 2011). The immune 
system communicates by sending out signals that lead to activation, recruitment, 
or allow for other physiological effects to occur. These signals are typically 
released from immune cells as cytokines or chemokines. Secreted cytokines 
recruit other cells such as macrophages and neutrophils, which respond by 
phagocytosing infected cells. 
 NK cells, derived from the same precursor cell as T and B cells, are a third 
subset of the lymphocyte population that participates in the body’s defense 
against viruses and intracellular pathogens (Abbas 2012). These cells are similar 
to cytotoxic T cells, but their cell surface receptors are different than those found 
on T and B cells.  
Macrophages are antigen-presenting cells (APC) of the mononuclear 
phagocytic system (MPS), which is a group of cells in which the primary function 
is to phagocytose foreign antigens (Abbas 2012). All cells of MPS are derived 
from a common precursor cell found in the bone marrow. Two major cell 
lineages are derived from a common precursor cell in the bone marrow called 
hematopoietic stem cells (HSCs). HSCs can become monocytes, which ultimately 
differentiate into macrophages and are activated in multiple tissues in the body. 
T helper cells that recognize antigen displayed on the cell surface by antigen 
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presenting cells activate macrophages; this causes the T helper cells to release 
cytokines that then activate the macrophages (Ross 2011). Macrophages are 
recruited to a site of infection by chemokines produced by T cells. T cells also 
secrete cytokines that induce other cells to release chemokines for macrophage 
recruitment.  
A second type of APC is a dendritic cell (DC) (Abbas 2012). DCs play a 
crucial role in innate immunity and activation of naïve T cells. These cells are 
characterized by long projections, referred to as dendritic processes, of their 
membrane. DCs mature in response to a cytokine called Flt3 ligand. They 
function by recognizing receptors expressed by microbes, phagocytosing the 
foreign pathogen, and presenting the antigen to circulating T cells which are then 
activated and can perform its functions. 
 Mast cells, similar to macrophages in origin, are derived from bone-
marrow cells present in mucosal epithelium (Abbas 2012). Mast cells contain 
granules in their cytoplasm filled with cytokines and histamine. Mature mast 
cells are not typically found in peripheral blood circulation, but are usually 
found within tissues near small blood vessels and nerves. Products released by 
microbes or via an antibody-dependent mechanism activate mast cells. When 
activated these cells release histamine, which is a vasoactive amine that causes 
vasodilation and increased capillary permeability. Mast cells also synthesize 
prostaglandins and cytokines, such as TNFα Because mast cells are common near 
blood vessels and nerves, the release of their contents causes changes in the 
blood vessels that lead to acute inflammation. Interleukin 12 (IL-12), a cytokine 
involved in CD4+ cell differentiation, is secreted by both macrophages and DCs. 
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The binding of this cytokine to its receptor on the surface of NK cells and T cells 
induces interferon gamma (IFNγ) synthesis and secretion. 
6.3 Immune Cell Involvement in the Menstrual Cycle 
 Northern et al (1994) conducted a study to determine peripheral 
lymphocyte concentrations in normal menstruating women and found that total 
white blood cells (WBCs) significantly increased in the blood during the day and 
peak around 2 pm on day six of the menstrual cycle. These levels then declined 
to their lowest point overnight. Differences were observed in cell counts during 
the normal menstrual cycle: white blood cells and B cells were significantly 
higher during the proliferative phase, whereas NK cells were significantly higher 
during the secretory phase. In general, this study found that daily total WBCs 
were lowest in the morning and peaked by 2 pm. 
 Lee et al (2010) conducted a study to see if the lymphocyte populations in 
peripheral blood varied during the menstrual cycle and found that all three 
lymphocyte populations fluctuated in response to ovarian phase. T cells were 
increased in the follicular phase compared to the luteal phase and NK cell levels 
and NK cell toxicity were significantly higher during the luteal phase than the 
follicular phase. While B cell concentrations changed during the menstrual cycle, 
these changes were not significant. 
6.4 Lymphocytes in Endometriosis 
 Current research suggests that abnormalities in the functions of the 
lymphocyte populations could be responsible for the pathology of this disease. 
As previously mentioned there are three subsets of the T lymphocyte population: 
CTLs, T helper cells, and T regs. Inhibition of the functions of these populations 
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has been observed in women with endometriosis as well as in surgically induced 
endometriosis animal models. Current research demonstrates that cytotoxic T 
lymphocytes that are unresponsive to autologous endometrium are present in 
endometriosis. In a study performed by Dmowski et al (1981) the cytotoxicity of 
T lymphocytes against autologous endometrium was observed to be significantly 
decreased in women with endometriosis. Decreased proliferation of lymphocytes 
in response to autologous endometrial cells was seen also in women with 
endometriosis (Helvacioglu 1997).  
A second method by which endometrial cells have demonstrated an 
ability to evade CTL immune surveillance is through cytokine-mediated 
expression of the transmembrane protein Fas Ligand (FasL). FasL belongs to the 
TNF family and induces apoptosis by binding to its receptor on adjacent cells. 
FasL expression by endometrial stromal cells is caused by the cytokine IL-8 and 
the chemokine CCL2 (Osuga 2011). Secretion of CCL2 by endometrial cells up-
regulates FasL mediated apoptosis in T-lymphocytes. This suggested method of 
evasion was further supported by two studies by Selam B et al (2002, 2006) that 
demonstrated that IL-8 and CCL2 were increased in the serum and peritoneal 
fluid of women with endometriosis.  
CD4+ and CD8+ T cell abundance or activity is altered in endometriosis. 
A few studies have shown a decreased CD4:CD8 ratio in endometriotic 
peritoneal fluid (Osuga 2011). CD4+ T helper cells also have decreased activity in 
women with endometriosis. While there were high levels of CD4+ T 
lymphocytes there were decreased levels of activated CD4+ T lymphocytes 
indicating that the activation of these cells has been suppressed in women with 
endometriosis. A study by Lee et al (2005) (Lee 2005) showed that THP1 cells, 
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cells of the monocyte cell lineage, exhibited decreased expression of MHC class II 
when co-cultured with endometriotic peritoneal fluid. MHC class II is a cell 
surface protein that plays a fundamental role in antigen recognition by CD4+ T 
cells (Abbas 2012). This protein is crucial in T cell activation and therefore its 
decreased expression associated with endometriosis could explain the decreased 
cytotoxicity of CD8+ T cells and the decreased activation of CD4+ T helper cells. 
Regulatory T cells, a recently discovered subpopulation of T lymphocytes, 
are important in suppressing the immune system (Osuga 2011). In women 
without endometriosis there is a significantly decreased level of regulatory T 
cells in peripheral blood circulation during the secretory phase of the menstrual 
cycle, while this was not observed in women with endometriosis. This suggests 
that the unsuppressed levels of T regs prevent the recruited immune cell 
populations from clearing the shedded endometrial tissue and therefore allow 
endometriotic tissue survival and implantation. 
The suggested role of B cells in the pathology of endometriosis is via 
secretion of autoantibodies. Badawy et al (1989) showed that the amount of IgG 
and IgA produced by peritoneal B cells was increased in women with 
endometriosis. This suggests an increased B cell activity in endometriosis. A 
second study by Odukoya et al (1995) also supports this idea of increased B cell 
activity. This lab observed increased serum concentrations of soluble CD23, a 
low affinity receptor for IgE that is produced by activated B cells, in patients with 
endometriosis. 
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6.5 Natural Killer Cells in Endometriosis 
 Natural Killer (NK) cells are responsible for tumor rejection as well as the 
removal of infected cells (Osuga 2011). As previously mentioned NK cells 
function by releasing small granules that induce apoptosis. Oosterlynx et al 
(1991) showed that in peripheral blood NK cells can destroy endometrial cells, 
which suggests the NK cell’s role in clearing refluxed endometrial cells in the 
peritoneum. NK cell activity was reduced in women with endometriosis (Viganò 
1991 and Garzetti 1993), which suggests that decreased NK cell cytotoxic activity 
potentially enables endometriosis development. Also, the reduced function of 
NK cell activity was correlated with the severity of endometriosis. 
6.6 Macrophages in Endometriosis 
Macrophage migration inhibitory factor (MIF), also called Glycosylation-
inhibiting factor, is a cytokine secreted by macrophages. MIF is an important 
immune system regulator and functions in inhibiting macrophage migration 
(Abbas 2012). MIF has also been shown to influence angiogenesis and cause 
inflammation. Increased levels of MIF were observed in the eutopic endometrial 
tissue of women with endometriosis. There were also significantly increased 
levels of MIF found in circulation and local peritoneal fluid and in active 
endometrial lesions.  
A study performed using an MIF inhibitor called (S, R) 3-(4-
hydroxyphenyl)-4,5-dihydro-5-isoxazole acetic methyl ester (ISO) decreased the 
number of endometriotic lesions observed in an in vivo animal model for 
endometriosis. The effects of ISO on apoptosis was also examined by looking at 
anti-apoptotic and pro-apoptotic factors. Bax, an important pro-apoptotic factor, 
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was shown to be upregulated in endometriotic lesions treated with ISO; whereas 
there was a significant decrease in protective Bcl2 expression in lesions also 
treated with ISO. 
6.7 The Role of Inflammatory Cytokines in Endometriosis 
 Various cells of the immune system secrete inflammatory cytokines such 
as TNFα, IL-6, and IL-12. Because endometriosis is characterized by pain 
associated with inflammation, the role of pro-inflammatory cytokines in the 
development of endometriosis has been examined. 
TNFα mRNA expression is increased in the endometrium and peritoneal 
fluid of women with endometriosis compared to healthy controls (Kyama 2006). 
Kim et al (2013) looked at the effects of both sex steroids and TNFα on a specific 
isoform of the Pak family, Pak4. Paks, also called P21-activated kinases, are a 
family of serine/threonine kinases that regulate cellular activities, such as 
apoptosis, cell motility, proliferation, and steroid receptor signaling (Lodish 
2008). Using siRNA-mediated knock down of Pak4 in endometrial glandular and 
stromal cells, Pak4 was shown to be responsible for cell motility in invasion 
assays. Treatment of endometrial glandular tissue with 10 ng/mL and 25 ng/mL 
of TNFα led to a significant increase in Pak4. Also, treatment of endometrial 
stromal cells with progesterone led to a significant decrease in Pak4 levels. Pak4 
was higher in the eutopic endometrium from patients with endometriosis and 
did not vary with menstrual cycle, unlike control patients that had lower Pak4 
levels during the secretory phase coincident with higher serum progesterone. 
This latter finding is consistent with higher Pak4 levels being associated with the 
endometriosis progesterone-resistant phenotype. 
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 Increased concentrations of IL-6 were also detected in the peritoneal fluid 
of women with endometriosis (Bersinger 2012). No fluctuations of these 
concentrations were observed throughout the menstrual cycle. IL-12 
concentrations were also increased, in endometriosis however, levels were 
significantly higher in the secretory phase of the uterine cycle. A summary of the 
cytokines mentioned in this section can be found in Table 6.1. 
6.8 Conclusions 
 The role of the immune system in endometriosis pathology, while not 
concrete is evident. Immune cell evasion and dysfunction are both linked to the 
ability of endometrial cells to implant and develop ectopically. Most cells of the 
immune system communicate through chemical signals, causing up and down-
regulation of other immune system secretions and effects. This suggests a 
combined contribution of immune cells and various cytokines to endometriosis 
pathology, which makes studies identifying the role of concurrent immune 
factors critical. 
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Chapter VII: Environmental and Dietary Factors 
7.1 Overview 
 Both environmental contaminants and dietary factors have been 
postulated to contribute to endometriosis.  This chapter discusses current 
research that potentially links environmental toxicant exposure and dietary 
factors to the development and progression of endometriosis. 
 Humans are constantly exposed to environmental toxins, particularly 
through the diet, which could potentially disrupt physiological processes 
possibly causing endometriosis (White 2009 and Bellelis 2011). Environmental 
toxins typically remain in the body for long periods of time due to their long 
half-life and can over time build up. This accumulation is due in part to the 
lipophilic nature of many of the environmental contaminants, which causes them 
to associate with and be stored in adipose and lipid rich tissues (White 2009). 
Environmental contaminants are being studied as potential endometriosis risk 
factors because of their ability to act as endocrine disruptors by altering steroid 
synthesis or hormone receptor function, disrupting immune function, and 
inhibiting reproductive function by epigenetic modifications (Bruner-Tran 2010).  
Dioxins like 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) are 
environmental contaminants and have been studied in relation to endometriosis.  
TCDD, the structure of which can be seen in figure 1.1, is one of the most well 
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studied chemical agents, because of its highly toxic nature (White 2009). In 
addition to dietary ingestion of environmental contaminants, other dietary 
constituents potentially contribute to endometriosis.  Theories regarding dietary 
influences on endometriosis include roles for dietary fatty acids, fiber and 
phytoestrogens (Parazzini 2013). 
7.2 TCDD 
TCDD belongs to a family of chlorinated hydrocarbons commonly 
referred to as dioxins (White 2009). These fat-soluble toxicants resist degradation 
and therefore accumulate in the food supply. This explains why ingestion of 
contaminated food is the primary method of exposure.  
TCDD typically enters the environment as an industrial by-product or 
from incineration (White 2009).  TCDD has as estimated half-life of 11.5 years, 
which explains the ability of this chemical to easily accumulate in the body upon 
consumption of contaminated food. TCDD was first looked at for its potential 
role in endometriosis when a primate colony developed a high incidence of this 
disease following chronic dietary exposure of TCDD.  TCDD levels are typically 
high in breast milk (Rier 2002). It has been reported that very high levels of 
TCDD are found in the breast milk of Belgium women, which interestingly has 
one of the highest endometriosis rates of any country.   
Current research has sought to find steroid-mediated endometrial tissue 
functions in which exposure to TCDD may alter or inhibit activity (Bruner-Tran 
2008). Thus far research supports a link between exposure to TCDD and the 
progesterone-resistant endometrial phenotype (Bruner-Tran 2010). As previously 
mentioned, retrograde menstruation is the most accepted theory of how 
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endometrial tissue makes its way into the peritoneal cavity, but it is the ability of 
the endometrial fragments to invade the peritoneal wall that determines the 
survival and growth of the endometrial tissue at ectopic sites; TCDD may 
influence this event. Metalloproteinases (MMPs) are enzymes needed for tissue 
invasion. TCDD in combination with estradiol has been shown to increase MMP 
expression and activity by endometrial stromal cells, providing a mechanism for 
TCDD promotion of endometriosis (Yu 2008). 
TCDD has a high affinity for the aryl hydrocarbon receptor (AhR), which 
is an orphan nuclear receptor that is considered to initiate the toxic effects of 
these compounds (Bruner-Tran 2008). Unbound AhR receptors, found in the 
cytosol, are associated with a complex of chaperone proteins. These receptor 
complexes are expressed in both endometrial and immune cells. The binding of 
either dioxin or dioxin-like compounds to AhR causes the chaperone proteins to 
dissociate and enables the AhR to enter the nucleus.  In the nucleus, the AhR 
rapidly forms a heterodimeric complex with an aryl hydrocarbon nuclear 
translocator (ARNT) protein. This process is shown is Figure 7.1. TCDD 
activation of the AhR leads to pro-inflammatory chemokine and cytokine 
production (Bellelis 2011).  TCDD potentially leads to the development of 
endometriosis by inhibiting the anti-inflammatory effects of progesterone. It has 
also been shown to function by increasing levels of specific interleukins and by 
activating enzymes like aromatase, which would in turn increase estrogen (Rier 
2002).  
TCDD in combination with estrogen and progesterone has been observed 
to induce endometriosis implantation and growth in animals.	   In a murine model 
of endometriosis immunocompromised athymic nude mice were used to implant 
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endometrial tissue from normal women and women with endometriosis (Bruner-
Tran 2008). The human tissue exposed to TCDD showed a higher amount of 
endoglin staining, a marker for cell proliferation, and exhibited a higher 
microvascular density at the peritoneal invasion site than the human tissue 
exposed to only estrogen and progesterone. In addition, many neutrophils were 
found in the endometrial stroma of the TCDD-exposed tissue. While low levels 
of neutrophils present in the lumen of endometrial glands is a normal occurrence 
in human endometrium during the secretory phase, increased neutrophil 
presence may be related to endometriosis pathology, due to their associations 
with early stages of inflammation and their production of the pro-angiogenic 
factor VEGF. 
TCDD has been shown to cause the progesterone-resistant phenotype seen 
in women with endometriosis (Bruner-Tran 2008, 2010). Two isoforms of 
progesterone receptor (PR), PR-A and PR-B, are present in endometrial tissue 
(Kim 2013). Estrogen typically increases both PRs in normal endometrium. In 
endometriotic tissue PR-A levels are lower than eutopic endometrium, and PR-B 
is not detectable (Attia 2000). TCDD is suspected of altering the PR isoform 
proportions expressed. 
PR-B isoform is the primary mediator of anti-inflammatory effects 
induced by progesterone (Osteen 2002), however PR-A, which is a truncated 
form of the PR, can dominantly suppress PR-B responses (Vegeto 1990).  In the 
progesterone-resistant phenotype associated with endometriosis patients, high 
levels of PR-A expression relative to PR-B are seen in both eutopic and ectopic 
endometrial tissue (Attia 2000). Bruner-Tran et al (2010) using a murine model 
observed that in utero and prepubertal TCDD exposure causes infertility, 
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inability to sustain pregnancy to term, and a significant decrease in PR. This was 
observed for several generations of the TCDD-exposed mice indicating, a 
possible epigenetic transmission or specific mutations. 
Another study produced similar results using adult endometrial stromal 
cells (Igarashi 2005). PR-B:PR-A ratios were significantly lower in endometrial 
stromal cells in women with endometriosis than in normal endometrial tissue 
from control patients. The same study exposed normal endometrial epithelial 
and stromal cells to the toxicant TCDD and observed a decrease in PR-B 
expression relative to PR-A. 
7.3 Dietary Factors 
Exposure to environmental toxins via ingestion of contaminated food is 
one way that diet potentially influences endometriosis pathology (Bellelis 2011). 
Normal dietary constituents themselves may play a role in endometriosis 
development or symptoms.  Some theories are present regarding dietary 
influences, but most correlative data is from individual case reports and reviews 
of epidemiological findings do not consistently support any single dietary factor 
association with endometriosis (Parazzini 2013).  Two topics worth noting are a 
potential influence of dietary fatty acids and modulation of estrogen content or 
action. 
Dietary fatty acids, found in various oils, serve as the substrate for many 
prostaglandins including prostaglandin-E2 (PGE2) and prostaglandin-F2alpha 
(PGF2α).  PGE2 and PGF2α are pro-inflammatory eicosanoids that may increase 
uterine contractions and cause pain or dysmenorrhea, a frequent symptom of 
endometriosis (Bellelis 2011). Peritoneal explants with endometriotic lesions 
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produce higher PGE2 and PGF2α than surrounding normal peritoneum 
indicating the lesions were the likely source of the prostaglandins (DeLeon 1988). 
Elevated PGE2 in the peritoneal cavity of individuals with endometriosis, was 
found to be attributed to both the macrophage population and ectopic 
endometrial cells (Sacco 2012). In addition, along with PGE2’s inflammatory 
effects, increased VEGF was found in both the peritoneal fluid and lesion 
implants of individuals with endometriosis (Li 2005).  
PGE2 has also been shown to play a potential role in endometriosis-
infertility (Lee 2011). Sperm treated with concentrations of PGE2 similar to those 
observed in women with endometriosis showed a decline in fertility caused by 
decreased rates of acrosome reaction, which occurs when necessary enzymes for 
penetration of the zona pellucida are released by the sperm upon contact with 
the egg (Ross 2011); and oocyte penetration. 
As mentioned previously, endometriosis is an estrogen-dependent 
disease.  Altering the level of circulating estrogens can influence endometriosis 
pathology.  Kaneda et al (1997) demonstrated in women that a diet containing 
low fiber showed increased estrogen concentrations and therefore low fiber 
intake could potentially be involved in endometriosis risk. Unfortunately, there 
is a lack of support for this idea, as data on crude fiber intake and endometriosis 
risk do not show a consistent association (Parazzini 2013). 
Another way estrogen action and thus endometriosis could be affected by 
diet is by the intake of phytoestrogens like those found in soy products.  
Soybeans contain isoflavones with estrogen-like properties.  Some of these 
molecules act as weak estrogen agonists and they may even compete with 
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endogenous estrogen for the estrogen receptors thereby lowering the effects of 
endogenous estrogens.  Two components of soy, genistein and puerarin, have 
been investigated using animal models of endometriosis.  These soy components 
led to a reduction of estrogen concentrations, estrogen receptor levels, and 
estrogen production (via aromatase) and in turn reduced size and weight of 
endometriotic lesions (Yavuz 2007 and Chen 2011). 
7.4 Conclusions 
 While these environmental toxins and dietary factors have been studied in 
relation to endometriosis development, there is not sufficient evidence to 
conclude a major role in endometriosis etiology. One reason why the correlation 
of chemical toxicant exposure to the ultimate development of endometriosis is 
difficult to assess may be that exposure in adults has less of an impact than early 
life exposure (Bruner-Tran 2008). It is suggested that toxicant exposure during 
fetal life and early development are more relevant to disease advancement due to 
the high sensitivity to these disruptors during this critical time in development.  
Determining the influence of natural dietary products on endometriosis 
development or progression needs long-term case-controlled studies to draw 




Figure 7.1 Chemical Structure of TCDD. Reprinted from Chemosphere, Volume 
91, Wenxiao Pan, Yuanyuan Qi, Ruoxi Wang, Zhe Han, Dongju Zhang, Jinhua 
Zhan, “Adsorption of TCDD with 1-butyl-3-methylimidazolium dicyanamide 
ionic liquid: A combined molecular dynamics simulation and quantum 
chemistry study,” 157-164, © 2013, with permission from Elsevier.
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Figure 7.2 The Proposed Mechanism of action of the dioxin TCDD. Reprinted 
from Environmental Toxicology and Pharmacology, Volume 10, Minghua Nie, 
Alan L. Blankenship, John P. Giesy, “Interactions between aryl hydrocarbon 
receptor (AhR) and hypoxia signaling pathways,” 17-27, © 2001, with permission 
from Elsevier.
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Chapter VIII: Genetic Influence and Polymorphisms 
8.1 Overview 
 Evidence suggests that inheritance patterns and genetic variation play a 
potential role in endometriosis pathogenesis (Hoffman 2011). Various mutated 
genes that have been passed down are currently being investigated for their role 
in this disease. Genetic mutation is responsible for inherited disease in humans 
(Lodish 2008). DNA polymorphisms are variations within the DNA sequence 
and can be followed throughout generations. Polymorphisms represent normal 
variation in a gene’s sequence at a particular site. Unlike mutations, polymorphic 
genes are not directly linked to disease, but they can influence an individual’s 
predisposition for a disease.  
Single nucleotide polymorphisms (SNPs) are the most frequent genetic 
variation and are single points in the genomic sequence in which one large 
percentage of the population has one nucleotide and another large percentage 
has another (Alberts 2002). If two human genomes taken from the world’s 
population were sequenced they would differ at approximately 2.5  x  10! points 
or about 1 per 1300 nucleotide pairs. Known sites of the human genome in which 
there is a high probability that the genomes of two people will differ are referred 
to as polymorphic sites.  There are two approaches currently used to find 
correlations between particular polymorphic genes and endometriosis including 
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sibling-pair linkage analysis and gene expression analysis via microarray 
technology (Hoffman 2011). This chapter discusses several various 
polymorphisms involving genes that regulate inflammation and immune 
response, estrogen receptors, and cell cycle regulation. There are many 
polymorphism studies that exist to date and new studies are constantly being 
published. This chapter will attempt to show a range of polymorphic genes that 
have been identified in various populations around the world.  
8.2 Specific Polymorphisms and Endometriosis 
8.2.1 NFκB 
NF-κB is a transcription factor that is important in inflammation and the 
immune response (Voet 2011). It is found in the cytosol of cells in an inactive 
state when it is bound to an inhibitor IκBα that prevents it from traveling into the 
nucleus. However, when pro-inflammatory cytokines such as TNFα and IL-1 
bind to cell surface receptors they initiate a signal transduction pathway that 
ultimately leads to phosphorylation and dissociation of IκBα. This enables NF-κB 
to translocate to the nucleus and activate transcription of its target genes.  
An insertion or deletion in the promoter region of the gene encoding the 
transcription factor NF-κB functions by decreasing the amount of RNA 
transcribed and in turn the amount of protein produced (Bianco 2012). In the 
Brazilian population, the insertion of the sequence ATTG causes a decrease in the 
production of NF-κB, which is positively correlated with moderate to severe 
endometriosis and infertility. 
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8.2.2 Estrogen receptors alpha and beta 
Because endometriosis is an estrogen-dependent disease, genes that code 
for estrogen receptors alpha and beta (ERα and ERβ) are being studied. ERα and 
ERβ are similar, but have different mechanisms of action, slight variations in 
their gene and protein structures, and are encoded by different genes on separate 
chromosomes (Berne 2004). Both estrogen receptors have similar DNA-binding 
domains, but the ligand binding domains are only 55% homologous in sequence. 
They are also found in different locations. ERα is mostly found in uterine 
endometrium, whereas ERβ is typically found in granulosa cells and osteoblasts. 
Both receptors have the same affinity for estradiol, but varying affinities for other 
forms of estrogen. Estradiol has different actions in various tissues depending on 
the presence of a single receptor form or the ratio between the two-receptor 
forms.  
Several studies examined ERα gene polymorphisms. In a Chinese 
population, a dinucleotide TA repeat (genotype E-14 repeats) in the ERα  
promoter was associated with endometriosis incidence (Hsieh 2005). In a 
Japanese population the PvuII polymorphic locus showed an increased incidence 
of the PP genotype with endometriosis (Kitawaki 2001). However, Sato et al 
(2008) examined additional intron 1 and exon 1 polymorphisms in the Brazillian 
population and concluded that neither of these additional sites correlated with 
increased risk of endometriosis in this population.  
A study by Silva (2011) looked at the RsaI gene polymorphism in the ERβ 
gene. A higher frequency of the heterozygous AG polymorphism was discovered 
in individuals with endometriosis compared to patients without endometriosis. 
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8.2.3 p53 
The transcription factor p53 is a tumor suppressor that oversees genome 
integrity (Voet 2011). It plays a critical role in arresting cells that have damaged 
DNA and preventing destructive transformation of cells. In response to damage 
this factor increases the ability of DNA to activate the transcription of specific 
genes that respond to and fix damaged DNA (Lodish 2008). 
Two studies examined p53 gene polymorphisms and the association with 
endometriosis risk. Ribeiro Júnior et al (2009) studied the Arg72Pro 
polymorphism in Brazilian women and found that the proline allele was 
significantly associated with intense pain and was more frequent in individuals 
with endometriosis. A second study by Govatati et al (2012) did not find an 
association between the p53 Arg72Pro polymorphism and endometriosis in 
Indian women; however, reduced expression of p53 was found in endometrial 
tissue in a small sample (n=5) of women with endometriosis. 
Conclusions 
 The polymorphisms listed above represent only a small sample of those 
that have been investigated. No one single polymorphism has been consistently 
associated with endometriosis risk across multiple populations. For such studies 
to be of value, it is necessary that the normal and endometriosis patient 
population that is evaluated be of sufficiently large size, as some prior studies 
that have shown associations between a disease and a single nucleotide 
polymorphism that have been negated when a larger sample size was included. 
Ethnic variations also exist, which can confound data and prevent one from 
identifying a single global polymorphism linked to endometriosis risk. 
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Figure 8.1 The predicted 3-D structure for Estrogen Receptor-alpha (ER-α) 
Kumar, Raj, Mikhail N Zakharov, Shagufta H Khan, Rika Miki, Hyeran Jang, 
Gianluca Toraldo, Rajan Singh, Shalender Bhasin, and Ravi Jasuja. 2011. The 
dynamic structure of the estrogen receptor. J Amino Acids 2011: 812540.
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Figure 8.2. The predicted 3-D structure for Estrogen Receptor-beta (ER-β)  
Kumar, Raj, Mikhail N Zakharov, Shagufta H Khan, Rika Miki, Hyeran Jang, 
Gianluca Toraldo, Rajan Singh, Shalender Bhasin, and Ravi Jasuja. 2011. The 
dynamic structure of the estrogen receptor. J Amino Acids 2011: 812540.
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Chapter IX: Animal Models 
9.1 Overview of Animal Models 
Due to the limited ability to perform experimental manipulations in 
humans, animal models have been developed in order to study the etiology of 
endometriosis. Humans and primates are the only mammals that develop 
spontaneous endometriosis and experiments involving primate models are 
incredibly expensive, which is why most studies involving primates have a small 
sample size. Small animal models using rodents that simulate this disease in 
humans have been developed in order to solve this dilemma; however, the 
differences between the human menstrual cycle and rodent estrous cycle present 
another problem with these studies. While there are limitations to studying this 
disease in the current animal models, such models have been useful for studying 
in vitro human samples, fetal development, and in vivo effects. This chapter will 
discuss the strengths, weaknesses, and findings of these endometriosis animal 
models. 
9.2 Laboratory Mouse Model 
 Apparent differences exist between human and murine reproductive 
processes, which are necessary to understand when studying the endometriosis 
models involving the common laboratory mouse. Instead of a menstrual cycle, 
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female mice have an estrous cycle that lasts approximately four to five days. In 
order to identify the stage of the estrous cycle in a mouse, it is easy to perform a 
vaginal swab and determine the predominance of various vaginal cell types 
present at any given time (Caligioni 2009).  
The 4-5 day estrous cycle can be divided into four stages: proestrus, 
estrus, metestrus, and diestrus respectively. The first stage of the cycle, proestrus, 
is characterized by a higher proportion of nucleated epithelial cells and 
occasionally keratinized cells in vaginal swabs. During proestrus, there is a thin 
layer of stratified squamous epithelium that begins to thicken and some of the 
epithelial cells undergo keratinization. This stage is the pre-ovulatory day when 
E2 increases, which results in the LH and FSH surge at night, and then ovulation 
occurs (Caligioni 2009). Estrus, the second stage of the estrous cycle, is identified 
by clusters of irregular shaped keratinized squamous epithelial cells with no 
visible nuclei. During estrus the stratified squamous epithelium has thickened 
and become fully keratinized. The superficial vaginal epithelial cells begin to 
disassociate and move into the lumen. The cytoplasm is observed to be granular 
and E2 remains elevated during the morning hours, but falls back to basal levels 
by the afternoon. 
Metestrus is characterized by low plasma E2 levels and a mix of vaginal 
cell types, a majority of them being leukocytes, a few nucleated epithelial and 
keratinized squamous epithelial cells. During metestrus regression of the 
epithelium also occurs. The leukocytes within the stroma infiltrate the 
epithelium. E2 levels begin to rise again in the final stage of the estrous cycle, 
diestrus, and the highest percentage of cells in a vaginal lavage smear will be 
leukocytes (Conti 2004). The epithelium has thinned and mucified during this 
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stage and many of the leukocytes in the stroma migrate into the lumen through 
the epithelium.  
A considerable physiological difference between mice and humans is that 
mice do not menstruate and therefore do not develop spontaneous 
endometriosis. This is a limitation of the murine model for endometriosis, but 
due to the low cost, the ability to study an in vivo setting, and the capacity to 
create knockouts for various genes in mice, the murine model is necessary. 
However, endometriosis must be induced in mice either surgically by implanting 
human endometrial tissue or by injecting endometrial tissue into the peritoneal 
wall (Tirado González 2010). There are two types of murine endometriosis 
models, the homologous model and the heterologous model, classified by the 
way in which the disease is induced. 
The homologous murine model of endometriosis is developed via either 
surgical transplantation or by peritoneal injection of endometrial tissue from 
another mouse of the same strain (Tirado González 2010). Similar endometrial 
models have been achieved in various rodent species such as mice, rats, and 
hamsters. The mice receiving the tissue develop endometrioic lesions on the 
peritoneal wall, on the intestines, and on the uterine surface. In these animal 
models, both the donor and recipient are ovariectomized in order to prevent 
hormonal feedback from the ovaries and are given estrogen in order to simulate 
the estrous cycle. In the donor mice the exogenous estrogen treatment allows for 
the growth and proliferation of viable endometrial tissue for translocation. 
However, the estrogen treatment in the recipient mice may influence the 
progression of the disease due to its dependence on estrogen. One of the main 
problems with this model besides the physiological differences in menstrual and 
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estrous cycles is that the endometrial lesions that develop in the murine models 
are much smaller and hard to distinguish. 
The heterologous model was created using the athymic nude mouse, 
which is immunocompromised and therefore can accept xenographs of human 
endometrial tissue (Zamah 1984). The nude mouse has a mutation that causes the 
failure of thymus development and lack of hair follicles (Abbas 2012). T cell 
maturation occurs in the thymus and therefore the nude mouse does not have a T 
cell response. In the murine heterozygous model for endometriosis human 
endometrial tissue is surgically implanted in the peritoneal wall in order to study 
the effects of this tissue. However, the use of this immunocompromised mouse to 
study endometriosis pathogenesis is lacking the immune response aspect that 
would normally be present and potentially involved in the disease development. 
This is a limitation of the heterologous model along with other previously 
mentioned restrictions of rodent models. 
9.3 Primate Model 
 Nonhuman primates are the only animals that have a menstrual cycle 
similar to humans. Merrill et al (1968) demonstrated that baboons are able to 
develop spontaneous endometriosis similar to humans, which is why they have 
been used as an animal model. A second study by D’Hoogne et al (1996) further 
supported this claim by observing histologically proven spontaneous 
endometriosis in a larger group of baboons over a three-year period. This study 
consisted of 67 laparoscopies performed on 24 baboons with normal pelvic 
cavities. These surgical procedures were done in 3-month intervals over a 32-
month period. However, a study by Harirchian et al (2012) showed that the 
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surgical incisions made during laparoscopies caused endometrial lesions to 
develop in their control group; therefore the endometriotic lesions observed in 
prior studies (Merrill 1968) may have been caused by the laparoscopies 
themselves and not have been a spontaneous occurrence. 
 The olive baboon, Papio Anubis, is the most commonly used primate 
model for endometriosis. It is an important model due to its reproductive 
anatomy and menstrual cycle similarity to that seen in women (Stevens 1997). 
Endometriosis can be induced in the baboon by endocervical canal resection 
(Dehoux 2011) or by injecting autologous endometrial tissue into the peritoneal 
cavity (Dhooghe 1997). Induction by endocervical canal resection requires the 
removal of part of the cervical canal. The canal is then cauterized in order to 
avert menstrual bleeding into the vagina, which simulates retrograde 
menstruation. The second method of induction involves removing endometrial 
tissue from the uterus of the baboon and then injecting it into the peritoneal 
cavity. Both methods of endometriosis induction have been shown to induce this 
disease for study. However, studies involving these animals are expensive and 
require years for preparation and procedure. 
9.4 Importance and Conclusions 
The use of non-human primate models of endometriosis provides an 
examination of potential factors involved in the development of this disease as 
well as dysfunction of the immune response. Due to the physiological 
reproductive similarities between non-human primates and humans a greater 
understanding of the human pathology of this disease can be discovered. 
Problems encountered with the baboon model of endometriosis are the high cost 
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and the time needed in order to develop a disease model, which is why rodent 
animal models are also necessary.  
Even with the limitations of both non-human primate and rodent models 
for comparative studies of endometriosis pathology, a lot has been learned about 
the factors and physiological disruption involved in the development and 
progression of this disease. 
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Chapter X: Endometriosis Treatments 
10.1 Overview 
Many pre-existing drugs have been used to treat endometriosis, however, 
because the etiology of this disease remains unknown, there is no cure. Due to 
years of research, understanding the involvement of certain factors has provided 
a method in which to treat particular symptoms. An important distinction, which 
must be made is whether a patient is looking for treatment of pain or infertility, 
because the treatment used will be based on the symptoms (Hoffman 2011). In 
patients with mild pain, NSAIDs, combination oral contraceptives, and 
progestins are used as treatment options; for infertility intrauterine 
inseminations in combination with empiric clomiphere is used. Moderate to 
severe pain as well as infertility in endometriosis patients can be treated with the 
surgical excision, ablation, and lysis of adhesions and further followed by post-
operative treatments, such GnRH agonists and aromatase inhibitors, in order to 
prevent recurrence. This chapter will examine treatment options for pain and 
infertility as well as review the current literature and experimental treatment 
options of endometriosis. 
10.2 Non-Steroidal Anti-Inflammatory Drugs 
Non-steroidal anti-inflammatory drugs (NSAIDs) work by non-selectively 
inhibiting cyclooxygenase isoenzymes. These enzymes function in prostaglandin
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synthesis, which is responsible for endometriosis-associated pain and 
inflammation (Hoffman 2011). Cyclooxygenase, also referred to as prostaglandin 
H! synthase, exists in mammals as two isozymes (COX-1 and COX-2). These 
enzymes have different functions, but very similar amino acid sequences. While 
COX-1 is responsible for synthesizing the prostaglandins that regulate the 
secretion of gastric mucus in the GI tract, COX-2 produces prostaglandins 
responsible for inflammation, pain, and fever (Lehninger 2008). Studies designed 
to test the effects of decreased prostaglandin synthesis on the symptoms of 
endometriosis by inhibiting COX-1, were associated with unpleasant side effects 
such as stomach irritation and other serious conditions. After discovery of the 
organic structures of COX-1 and COX-2 in the 1990s, NSAID compounds were 
created that were specific to COX-2 in order to prevent negative effects of 
inhibition of both.  
Ota et al (2001) demonstrated that ectopic endometrial tissue expresses 
higher levels of COX-2 than eutopic endometrium. Efstathiou et al (2005) using 
an in vivo treatment of a murine endometriosis model, found that NSAIDs 
produces differential suppression of endometriotic lesion establishment and 
growth as compared to controls. Also, Laschke et al (2007) showed that treatment 
of a murine model of endometriosis with COX-2 inhibitor showed a 57% 
reduction in endometrial lesions compared to controls. In addition, COX-2 
inhibitors decreased cell proliferation and VEGF levels, which ultimately 
resulted in smaller endometriotic lesions and suppression of angiogenesis. 
Although these animal models have shown disease regression with NSAID 
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treatment, few studies have critically evaluated the effectiveness of disease 
regression in women with surgically confirmed endometriosis (Hoffman 2011).  
While there is good evidence for pain relief in women with dysmenorrhea 
and pelvic pain using COX-2 inhibitors, the long-term use of these drugs can 
cause cardiovascular problems, and should therefore be used in moderation and 
for as short a period of time as possible (Nasir 2004). For this reason, other 
methods of disease regression are also being studied. 
10.3 Combination Oral Contraceptives 
 Combination oral contraceptives were introduced in the United States 
(US) in May 1960 as a method of family planning and pregnancy prevention 
(Hatcher 2007). The first oral contraceptive, Enovid, contained 150 µg of 
mestranol and 9.85 mg of norethynodrel. These high levels of hormones were 
used due to their effectiveness and because studies had not been performed to 
identify the lowest effective dose. Today, the concentration of steroid hormones 
found in combined oral contraceptives (COCs) has declined dramatically, which 
have made these drugs much safer and lessened their side effects. All COCs have 
an estrogen and progestin component, which interact with each other. Synthetic 
progestins have higher androgenic effects, which can counter some of the 
metabolic impact of estrogen on the body; while estrogen can also suppress some 
of the progestin effects. These hormone interactions are dependent upon the 
concentration of estrogen and progestin in a particular pill. 
 Two forms of estrogen are used in COCs in the United States, including 
mestranol and ethinyl estradiol (EE) (Hatcher 2007). Mestranol is a drug 
precursor, which must first be metabolized by the liver into EE before it becomes 
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biologically active and effects can take place. Fifty micrograms of mestranol is 
equivalent to 35-40 µg of EE, which is more potent and has a longer action time 
than the steroid estradiol normally produced by the body. In COCs prescribed in 
the US, EE varies from 20 µg to 50 µg per pill. Progestins, the second component 
of COCs, are found in eight different forms in the US. Natural progesterone is 
not very well absorbed by the GI tract, is readily metabolized, and high doses 
cause fatigue. For these reasons, COC developers began looking at long-lasting 
compounds (C-19 androgens) to use as the progestin component of the pill rather 
than natural forms.  
The eight different progestins have made up various COCs and exist 
under different “progestin generations” that have developed over time (Hatcher 
2007). The first generation of progestins includes norethindrone, norethindrone 
acetate, and ethynodiol diacetate. When low dose amounts of progestin are used, 
typically norethindrone will be included. The main side effects of the first 
generation progestins was spotting and untimely bleeding. In an attempt to 
control the side effects of the first generation, the second generation of 
progestins, was created. These progestins (norgestrel and levonorgestrel) are 
more potent, have incredibly long half-lives, and have more androgenic activity 
than the first generation of progestins. A third generation of progestins 
(desogestrel and norgestimate) was created to exert a lower androgenic activity 
than the second generation and to main an increased progestational activity. The 
decreased androgenic activity of these third generation progestins allowed for a 
fuller metabolic effect of the COCs estrogen component. 
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 There are two formulations of COCs available: monophasic and 
multiphasic. Monophasic contraceptive indicates that each active pill is 
composed of the same doses of the estrogen and progestin as the other active 
pills; whereas multiphasic signifies that the amounts of hormones in the active 
pills vary (Hatcher 2007). Traditionally, monophasic COCs are prescribed for the 
treatment of endometriosis, but no studies offer proof in support of their clinical 
superiority to multiphasic COCs (Hoffman 2011). 
The mechanism of action of COCs includes reducing menstrual flow and 
potentially the volume of retrograde menses, decreasing GnRH pulses and 
pituitary responsiveness to GnRH stimulation, suppression of LH and FSH 
synthesis, and in some cases suppressing the mid-cycle LH surge (Maia 2008). By 
suppressing the hormones required for ovulation, ovarian estradiol production 
decreases, removing the stimulus for endometriotic implants and reducing the 
risk of developing endometriotic lesions. COCs also work by causing the pseudo-
decidualization of these endometriotic lesions. Pseudo-decidualization is caused 
by progestin induction of terminal differentiation of endometrial cells, which 
stops their growth. The progestin component of COCs, therefore results in 
reduced symptoms of endometriosis during use. However, this treatment does 
not cure the disease, because lesions only stop growth during treatment and are 
ready for re-growth when COC use is discontinued (Hatcher 2007). 
10.4 Surgical Treatment of Endometriosis 
 The principle manner in which endometriosis diagnosis is confirmed is 
via laparoscopy; for this reason, surgical treatment of the disease at the time of 
diagnosis seems appropriate (Hoffman 2011). Surgery can be used to treat either 
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symptom of endometriosis—moderate to severe pain or infertility. The benefits 
of surgery for individuals with severe forms of this disease include a mended 
pelvic anatomy, excision of implanted endometriotic lesions, and ultimately 
decreased inflammation (Macer 2012). There are two methods of endometriotic 
lesion removal: excision or ablation. Excision involves the complete removal of 
the lesion and ablation entails the destruction of ectopic endometrial tissue with 
conventional electrosurgery or a high-energy laser.  
According to a study by Blackwell et al (1991) laser ablation does not 
prove to be more effective than electrosurgery. However, regarding laparoscopic 
ablation versus the excision of endometriomas, excision was associated with a 
subsequent increased spontaneous pregnancy rate in women who were 
documented as infertile. A randomized controlled study consisting of 341 
women was conducted in order to discover whether laparoscopic surgery 
increased the fertility rate of endometriosis-associated infertility. It was 
concluded that ablation of endometriotic lesions significantly enhanced the 
fertility of women compared with diagnostic laparoscopy alone (Macer 2012). 
 Vercellini et al (2013) compared surgical treatment of endometriosis 
(ablation via electrosurgery) to a low-dose progestin treatment for disease-
associated deep dyspareunia in 192 women diagnosed with stage III and IV 
endometriosis. This study compared the Female Sexual Function Index (FSFI), a 
19-item questionnaire that evaluates the major groups of female sexual 
dysfunction and sexual satisfaction, of individuals undergoing surgery to those 
taking a progestin treatment. Patients that received surgery observed a 
substantial and rapid benefit (increased FSFI score) compared to the progestin 
treatment group. However, over the course of the study, performance of the 
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surgery group on the FSFI deteriorated and no significant difference was 
observed between the two groups in the long term.  
These studies indicate an initial suppression of symptoms after ectopic 
endometrial implants are removed, but suggest a recurrence of symptoms 
potentially due to regrowth of endometriotic lesions months after the initial 
excision. Also, the surgery itself can potentially cause other lesions to grow 
(Harirchian 2012), which also may be responsible for the return of endometriosis-
associated pain. Typically post-operative treatments for both pain and infertility 
are necessary for successful liberation from symptoms. However, even with a 
combination of surgery and post-operative treatments, a percentage of patients 
have a recurrence of symptoms. 
10.5 Post-operative Treatments 
In two studies of 95 participants a statistically significant reduction in the 
recurrence of dysmenorrhea was observed in a group that received post-
operative treatment than in the control group that only had surgery (AbouSetta 
2013). The post-operative treatment in this review was a levonorgestrel-releasing 
intrauterine device (IUD). As previously mentioned levonorgestrel is a potent 
progestin that decreases the metabolic activity of estrogen. This treatment 
suppresses the effects of estrogen and has a similar mechanism of action to the 
other post-operative treatments that are used. 
GnRH causes the release of the gonadotropin hormones and subsequent 
ovarian steroidogenesis and ovulation. However, continuous, nonpulsatile 
GnRH administration causes the anterior pituitary to become desensitized and 
decrease ovarian steroidogenesis (Hoffman 2011). This result allows GnRH 
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agonists to be used to treat endometriosis. Ultimately, GnRH agonists cause loss 
of estradiol production, which is necessary for the implantation and 
development of endometriotic lesions. This post-operative treatment allows for a 
pseudo-menopausal state and allows the body to recover, while simultaneously 
suppressing the disease from reforming.  
The third class of post-operative treatments, aromatase inhibitors, works 
by a mechanism similar to that of its counterparts. As previously mentioned 
aromatase is an enzyme that catalyzes the conversion of testosterone to estrogen; 
therefore aromatase inhibitors would decrease the amount of estrogen produced 
by the ovaries. In one study, aromatase inhibitors were used for the treatment of 
severe menopausal endometriosis (Takayama 1998). This treatment was given 
after a woman underwent a complete hysterectomy and a bilateral salpingo-
oophorectomy, in which both of the woman’s ovaries and fallopian tubes were 
removed. This individual experienced significant pain relief and reduction of 
lesion size after nine months. A second study, involving a baboon model for 
endometriosis, showed a significant reduction in endometrial ectopic lesion size 
when treated with aromatase inhibitors, whereas the control group given a 
placebo experienced endometrial lesion growth (Langoi 2012). These post-
operative treatments have shown to be necessary in successful suppression of 




Chapter XI: Conclusion 
Many factors play a role in the development and pathology of 
endometriosis, which explains why the etiology of this disease remains elusive. 
Current research supports the theory of retrograde menstruation along with the 
dysfunction of the immune response to misplaced endometrial tissue and 
increased secretion of angiogenic factors by ectopic endometrium. Other such 
factors that potentially increase endometriosis-associated inflammatory 
responses are environmental toxicants and inherited genetic variation, otherwise 
known as single-nucleotide polymorphisms, which alter various genes that are 
potentially involved in endometriosis pathogenesis.  
The only method to absolutely diagnose endometriosis is by surgical 
laparoscopy. Because it has been discovered that surgery alone can induce 
endometrial lesion formation, alternative modes of diagnosing endometriosis, 
such as by ultrasound, should be a developed. The current classification system 
of endometriosis by the American Fertility Society does not provide information 
on the severity of pain or fecundity. The Endometriosis Fertility Index attempts 
to bridge this gap, however, it is not currently a widely accepted method of 
identifying fertility in endometriosis patients. In order for preventative measures 
to be taken an endometriosis-associated pain predictor is needed. 
  Animal models, even with their limitations, have brought us steps 
closer to understanding steroid responses, angiogenic and immunologic factors
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produced in vivo, and the role of certain genes using knock-out mice. However, 
a higher level of understanding may not be obtained without more clinical trials. 
Treatments exist to aid in suppressing the symptoms of endometriosis, but due 
to the elusive nature of the disease, there is no cure. Endometriosis is a complex, 
multi-factorial disease; and while we’ve gained valuable knowledge on the 
potential factors involved, further research is necessary to achieve a better 
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